9-19-Cyclolanost-24-en-3-ol






Names

    • 3PQR2YON9T
    • DSSTox_GSID_21084
    • AKOS040757309
    • Tox21_112482
    • 11042-64-1
    • NCGC00181756-01
    • 9,19-CYCLO-9.BETA.-LANOST-24-EN-3.BETA.-OL, 4-HYDROXY-3-METHOXYCINNAMATE
    • Cycloartenyl ferulate
    • D01221
    • Oliver
    • Cycloartenol Trans-Ferulate
    • 286011-27-6
    • 9,19-CYCLOLANOST-24-EN-3-OL, (2E)-3-(4-HYDROXY-3-METHOXYPHENYL)-2-PROPENOATE, (3.BETA.)-
    • CS-0103198
    • 9,19-Cyclo-9beta-lanost-24-en-3beta-ol 4-hydroxy-3-methoxycinamate
    • Gamma oryzanol [JAN]
    • Gammariza
    • gamma Oryzanol
    • 9,19-CYCLOLANOST-24-EN-3-OL, 3-((2E)-3-(4-HYDROXY-3-METHOXYPHENYL)-2-PROPENOATE), (3.BETA.)-
    • UNII-3PQR2YON9T
    • SCHEMBL718726
    • BDBM50483936
    • OZ
    • 21238-33-5
    • Oryzanol A
    • CCG-270201
    • CCRIS 4251
    • HY-125938
    • Tox21_112482_1
    • DA-52220
    • J-002421
    • DSSTox_CID_1084
    • EINECS 244-285-1
    • gamma -Oryzanol
    • Cycloartenol ferulate
    • Cycloartenol, trans-ferulate
    • 9-19-Cyclolanost-24-en-3-ol
    • gamma Oryzanol (JAN)
    • Cycloartenol ferulic acid ester
    • s3957
    • Hi-Z (TN)
    • AKOS016339566
    • CHEMBL388595
    • E88692
    • CHEBI:32345
    • Q27257875
    • DSSTox_RID_75932
    • (3beta)-9,19-Cyclolanost-24-en-3-yl 4-hydroxy-3-methoxycinnamate
    • HI-Z
    • Oryzanol
    • SST9XCL51M
    • 9,19-CYCLO-9.BETA.-LANOST-24-EN-3.BETA.-OL 4-HYDROXY-3-METHOXYCINAMATE
    • CINNAMIC ACID, 4-HYDROXY-3-METHOXY-, 9,19-CYCLO-9.BETA.-LANOST-24-EN-3.BETA.-YL ESTER
    • 9,19-CYCLOLANOST-24-EN-3-OL, 3-(4-HYDROXY-3-METHOXYPHENYL)-2-PROPENOATE, (3.BETA.)-
    • UNII-SST9XCL51M
    • gamma-Oryzanol
    • ORYZANOL A [MI]
    • Ferulic acid cycloartenol ester
    • [(1S,3R,6S,8R,11S,12S,15R,16R)-7,7,12,16-tetramethyl-15-[(2R)-6-methylhept-5-en-2-yl]-6-pentacyclo[9.7.0.01,3.03,8.012,16]octadecanyl] (E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate
    • CAS-11042-64-1
    • gamma-Orizanol
    • 3-O-Ferulylcycloartenol
    • 9,19-Cyclolanost-24-en-3-ol, 3-[(2E)-3-(4-hydroxy-3-methoxyphenyl)-2-propenoate], (3.beta.)-
    • gamma-Oryzanol (TN)

Attributes

  • Canonical SMILES

    C[C@@H]([C@H]1CC[C@]2(C)[C@]1(C)CC[C@]34[C@H]2CC[C@H]5[C@@]3(CC[C@H](O)C5(C)C)C4)CC/C=C(C)\C

  • InChI

    InChI=1S/C30H50O/c1-20(2)9-8-10-21(3)22-13-15-28(7)24-12-11-23-26(4,5)25(31)14-16-29(23)19-30(24,29)18-17-27(22,28)6/h9,21-25,31H,8,10-19H2,1-7H3/t21-,22-,23-,24+,25+,27-,28+,29-,30+/m1/s1

  • Molecule Class: Terpenoids
  • TPSA: 20.23
  • #RotBonds: 4
  • MW: 426.7290000000002
  • HBD: 1
  • HBA: 1
  • logP: 8.168900000000008
  • Chemical Formula: C30H50O


Species

    Species Place of Collection NCBI Taxonomy Voucher Specimen
    T. catharinensis Brazil 403124 UEC117862

External Databases


References

  • Chromatographic analysis and antioxidant capacity of Tabernaemontana catharinensis. Nat Prod Commun, 2014 (PMID 24660464).

Compound-Protein Relationships


Compound Activities

    • Antioxidant

Predicted NMR Spectral Data


Predicted MS Fragmentation Pattern

    N.B.: It is recommended to zoom in on a specific area of an MS plot before hovering on a peak.

Predicted ADMET Properties

    Property Model Name Predicted Value
    Absorption Caco-2 (logPaap) -4.78
    Human Oral Bioavailability 20% Bioavailable
    Human Intestinal Absorption Absorbed
    Madin-Darby Canine Kidney -4.52
    Human Oral Bioavailability 50% Bioavailable
    P-Glycoprotein Inhibitor Non-Inhibitor
    P-Glycoprotein Substrate Non-Substrate
    Skin Permeability -3.1
    Distribution Blood-Brain Barrier (Central Nervous System) -1.75
    Blood-Brain Barrier Penetrable
    Fraction Unbound (Human) 1.81
    Plasma Protein Binding 89.23
    Steady State Volume of Distribution 1.55
    Metabolism Breast Cancer Resistance Protein Non-Inhibitor
    CYP 1A2 Inhibitor Non-Inhibitor
    CYP 1A2 substrate Non-Substrate
    CYP 2C19 Inhibitor Non-Inhibitor
    CYP 2C19 substrate Substrate
    CYP 2C9 Inhibitor Non-Inhibitor
    CYP 2C9 Substrate Non-Substrate
    CYP 2D6 Inhibitor Non-Inhibitor
    CYP 2D6 Substrate Non-Substrate
    CYP 3A4 Inhibitor Non-Inhibitor
    CYP 3A4 Substrate Substrate
    OATP1B1 Non-Inhibitor
    OATP1B3 Non-Inhibitor
    Excretion Clearance 7.92
    Organic Cation Transporter 2 Non-Inhibitor
    Half-Life of Drug Half-Life < 3hs
    Toxicity AMES Mutagenesis Safe
    Avian Safe
    Bee Toxic
    Bioconcentration Factor 0.63
    Biodegradation Safe
    Carcinogenesis Safe
    Crustacean Toxic
    Liver Injury I Toxic
    Eye Corrosion Safe
    Eye irritation Safe
    Maximum Tolerated Dose 1.25
    Liver Injury II Safe
    hERG Blockers Toxic
    Daphnia Maga 6.57
    Micronucleos Safe
    NR-AhR Safe
    NR-AR Toxic
    NR-AR-LBD Toxic
    NR-Aromatase Safe
    NR-ER Safe
    NR-ER-LBD Safe
    NR-GR Safe
    NR-PPAR-gamma Safe
    NR-TR Safe
    T. Pyriformis -55.73
    Rat (Acute) 2.17
    Rat (Chronic Oral) 1.89
    Fathead Minnow 3.92
    Respiratory Disease Toxic
    Skin Sensitisation Toxic
    SR-ATAD5 Safe
    SR-ARE Safe
    SR-HSE Safe
    SR-MMP Safe
    SR-p53 Safe
    General Properties Boiling Point 406.71
    Hydration Free Energy -3.15
    Log(D) at pH=7.4 7.53
    Log(P) 8.71
    Log S -7.18
    Log(Vapor Pressure) -7.77
    Melting Point 190.27
    pKa Acid 12.84
    pKa Basic 8.3